Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study

Beclometasone dipropionate (BDP) is a relatively new topically acting oral steroid to treat mild to moderately active ulcerative colitis (UC). We estimate that 20,000 patients have received oral BDP in Spain in the last two years. Our aim was to evaluate the efficacy and safety of oral BDP in clinic...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Crohn's and colitis 2010-12, Vol.4 (6), p.629-636
Main Authors: Nunes, Tiago, Barreiro-de Acosta, Manuel, Nos, Pilar, Marin-Jiménez, Ignacio, Bermejo, Fernando, Ceballos, Daniel, Iglesias, Eva, Gomez-Senent, Silvia, Torres, Yolanda, Ponferrada, Angel, Arevalo, José A, Hernandez, Vicent, Calvet, Xavier, Ginard, Daniel, Monfort, David, Chaparro, Maria, Manceñido, Noemi, Domínguez-Antonaya, Mercedes, Villalón, César, Perez-Calle, José L, Muñoz, Carmen, Nuñez, Henar, Carpio, Daniel, Aramendiz, Roberto, Bujanda, Luis, Estrada-Oncins, Silvia, Hermida, Carlos, Barrio, Jesus, Casis, M Begoña, Dueñas-Sadornil, M Carmen, Fernández, Luis, Calvo-Cenizo, M Mar, Botella, Belen, de Francisco, Ruth, Ayala, Edgar, Sans, Miquel
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Anti-Inflammatory Agents - administration & dosage
Anti-Inflammatory Agents - therapeutic use
Beclomethasone - administration & dosage
Beclomethasone - therapeutic use
Colitis, Ulcerative - drug therapy
Drug Administration Schedule
Female
Humans
Male
Remission Induction
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Beclometasone dipropionate (BDP) is a relatively new topically acting oral steroid to treat mild to moderately active ulcerative colitis (UC). We estimate that 20,000 patients have received oral BDP in Spain in the last two years. Our aim was to evaluate the efficacy and safety of oral BDP in clinical practice. Retrospective and multicenter study that included 434 patients with active UC treated with BDP. The partial Mayo Clinic score (pMS, 0-9) was used to measure disease activity. Remission was defined as post-treatment pMS of 0 or 1; response as a decrease in pMS of 3 points or 2 points and >30%, and failure as lack of remission or response. BDP dose was 5 mg/day in 88% of patients and mean treatment duration was 6.2 weeks. BDP achieved remission in 44.4%, response in 22.3% and failed in 33.2% of patients. Mean pMS decreased from 4.9 ± 1.3 to 2.4 ± 2.3 (p
ISSN:1873-9946
1876-4479
DOI:10.1016/j.crohns.2010.07.003